Baseline demographic and disease-related characteristics (intent-to-treat population)
| Characteristic . | . |
|---|---|
| Median age (range), y | 64 (38-88) |
| Sex, no. (%) | |
| Male | 123 (55) |
| Female | 99 (45) |
| Median time from first pathologic diagnosis (range), y | 3.7 (0.4-19.8) |
| ECOG performance status, no. (%) | |
| 0 | 71 (32) |
| 1 | 112 (50) |
| 2 | 26 (12) |
| Missing | 13 (6) |
| Median no. of prior treatment regimens including SCT (range) | 5 (3-21) |
| No. of prior autologous SCTs, no. (%) | |
| 0 | 122 (55) |
| 1 | 9 (4) |
| More than 1 | 91 (41) |
| No. of prior anti–multiple myeloma treatment regimens, not including SCT, no. (%) | |
| 1 | 18 (8) |
| 2 | 55 (25) |
| 3 | 47 (21) |
| More than 3 | 102 (46) |
| Prior therapies, no. (%) | |
| Radiotherapy | 96 (43) |
| Thalidomide | 177 (80) |
| Dexamethasone | 152 (68) |
| Bortezomib | 96 (43) |
| Melphalan | 94 (42) |
| Doxorubicin | 19 (9) |
| Characteristic . | . |
|---|---|
| Median age (range), y | 64 (38-88) |
| Sex, no. (%) | |
| Male | 123 (55) |
| Female | 99 (45) |
| Median time from first pathologic diagnosis (range), y | 3.7 (0.4-19.8) |
| ECOG performance status, no. (%) | |
| 0 | 71 (32) |
| 1 | 112 (50) |
| 2 | 26 (12) |
| Missing | 13 (6) |
| Median no. of prior treatment regimens including SCT (range) | 5 (3-21) |
| No. of prior autologous SCTs, no. (%) | |
| 0 | 122 (55) |
| 1 | 9 (4) |
| More than 1 | 91 (41) |
| No. of prior anti–multiple myeloma treatment regimens, not including SCT, no. (%) | |
| 1 | 18 (8) |
| 2 | 55 (25) |
| 3 | 47 (21) |
| More than 3 | 102 (46) |
| Prior therapies, no. (%) | |
| Radiotherapy | 96 (43) |
| Thalidomide | 177 (80) |
| Dexamethasone | 152 (68) |
| Bortezomib | 96 (43) |
| Melphalan | 94 (42) |
| Doxorubicin | 19 (9) |
All patients were treated with lenalidomide, N = 222.
ECOG indicates Eastern Cooperative Oncology Group; and SCT, stem cell transplantation.